Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

K. Papp*, D. Thaçi, K. Reich, E. Riedl, R. G. Langley, J. G. Krueger, A. B. Gottlieb, H. Nakagawa, E. P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames

*Corresponding author for this work
95 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science